GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Nanobiotix S.A.
Nanobiotix is a biotechnology company developing a new class of nanoparticle-based drugs to enhance cancer radiation therapy. Its stock price represents a venture bet on the success of its innovative technology, contingent on the results of clinical trials.
Share prices of companies in the market segment - Oncology platforms
Nanobiotix S.A. is a biotechnology company developing a new approach to cancer treatment using nanoparticles that enhance the effectiveness of radiation therapy. We classify it as part of the Oncology Platforms segment, where breakthrough technologies are created. The chart below reflects the dynamics of this entire innovative and risky sector.
Broad Market Index - GURU.Markets
Nanobiotix is a French biotech company that has developed nanoparticles that enhance the effectiveness of radiation therapy in cancer treatment. Its shares (ADR) are part of the GURU.Markets index. The chart below shows how its performance compares to the overall US market.
Change in the price of a company, segment, and market as a whole per day
NBTX - Daily change in the company's share price Nanobiotix S.A.
For Nanobiotix, a biopharmaceutical company, change_co is a measure of innovation volatility. Daily fluctuations reflect news about clinical trials of its radiation therapy platform. This metric forms the basis for biotech company analysis on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Oncology platforms
Nanobiotix S.A. is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with NBTX, with its unique radiation therapy-enhancing technology, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Nanobiotix is a biopharmaceutical company developing radio-enhancing nanoparticles to enhance the effectiveness of cancer radiation therapy. Oncology is a highly volatile sector. The chart below reflects average fluctuations in this industry, providing context for evaluating Nanobiotix shares.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Nanobiotix S.A.
Nanobiotix is a French biotech company developing cancer treatments. Its US-listed shares bring the dynamism of the European biotech sector to the market. These international factors complicate the overall market volatility picture.
Annual dynamics of market capitalization of the market segment - Oncology platforms
Nanobiotix S.A. is a late-stage biotech company developing a new class of drugs that enhance the effectiveness of radiation therapy in cancer treatment. Its stock price reflects the enormous potential of its breakthrough technology and the regulatory risks associated with bringing a new drug to market.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Nanobiotix is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of its platform for improving cancer radiation therapy. The company's chart exists in a world of its own, where data releases are the key events.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Nanobiotix S.A.
BlueLinx, a building materials distributor, has monthly fluctuations on the chart that directly reflect the state of the housing construction market. Lumber prices and demand for other building materials are key factors influencing its revenue.
Monthly dynamics of market capitalization of the market segment - Oncology platforms
Nanobiotix is a biotech company developing a platform to enhance the effectiveness of radiation therapy in cancer treatment. The oncology sector is attracting significant investment. The industry's dynamics reflect the hopes for new methods of fighting cancer. Nanobiotix's story is a bet that its technology will become a new standard, improving treatment outcomes for millions of patients.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Nanobiotix is a biotech company developing a new approach to cancer radiation therapy using nanoparticles that enhance the effects of radiation. Its value depends almost entirely on the success of clinical trials. The overall market price has little impact on Nanobiotix; its shares are driven by scientific news, which can cause explosive gains or losses on any given day.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Nanobiotix S.A.
Nanobiotix, which develops an innovative approach to cancer radiation therapy, is extremely sensitive to scientific news. Weekly stock price movements reflect the publication of clinical trial data and steps toward commercializing its technology.
Weekly dynamics of market capitalization of the market segment - Oncology platforms
Nanobiotix operates in the revolutionary nanomedicine sector, where shared technological breakthroughs and regulatory decisions impact everyone. The success of one company can boost the entire sector, while failure can dampen investor interest. The chart will show whether the market perceives NBTX as a leader in this movement or simply part of it.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
As a biotech company, Nanobiotix often ignores broader market trends. Its fate depends not on GDP or inflation, but on the results of clinical trials. The chart below clearly demonstrates how NBTX shares can rise or fall on their own news, while the overall market moves in a different direction.
Market capitalization of the company, segment and market as a whole
NBTX - Market capitalization of the company Nanobiotix S.A.
The Nanobiotix chart is a visual representation of the hopes for a revolution in cancer radiation therapy. This biotech company's market capitalization is based on its unique nanoparticle technology that enhances the effects of radiation. Its sharp fluctuations reflect investors' reaction to clinical trial data and the potential to change the standard of treatment.
NBTX - Share of the company's market capitalization Nanobiotix S.A. within the market segment - Oncology platforms
Nanobiotix is developing an innovative nanoparticle-based platform to enhance the effectiveness of radiation therapy in cancer treatment. Its share of the oncology market capitalization reflects the breakthrough potential of its technology. The chart below illustrates the valuation volatility typical of biotech companies in clinical trials.
Market capitalization of the market segment - Oncology platforms
Nanobiotix is developing an innovative approach to cancer treatment using nanoparticles to enhance the effectiveness of radiation therapy. The chart below shows the market capitalization of the oncology platform sector. This represents an assessment of the industry seeking breakthrough technologies to defeat cancer.
Market capitalization of all companies included in a broad market index - GURU.Markets
Nanobiotix is a biotech company developing a new approach to cancer radiation therapy using nanoparticles to enhance its effectiveness. The company's market cap is a bet on a breakthrough in oncology. On a pharmaceutical industry-wide scale, its value reflects investors' belief that physics can help make cancer treatment more effective and safe.
Book value capitalization of the company, segment and market as a whole
NBTX - Book value capitalization of the company Nanobiotix S.A.
Nanobiotix is based on revolutionary technology. The company's book value comes from its intellectual property rights to nanoparticles that enhance the effectiveness of radiation therapy, as well as the funds it has to conduct global clinical trials of this oncology platform. The chart below shows how the company is raising capital to bring its breakthrough idea to market.
NBTX - Share of the company's book capitalization Nanobiotix S.A. within the market segment - Oncology platforms
Nanobiotix develops nanoparticles for cancer treatment in its cutting-edge laboratories. This unique research and production base is its main material asset. The S_BCap_Seg graph shows the company's share of the innovative infrastructure of oncology platforms.
Market segment balance sheet capitalization - Oncology platforms
Against the backdrop of the capital-intensive pharmaceutical industry with its gigantic factories, Nanobiotix has chosen the path of a technological innovator. Its value lies in its nanoparticle platform. The graph illustrates the material strength of the industry, while Nanobiotix builds its success on science, not on scale.
Book value of all companies included in the broad market index - GURU.Markets
Nanobiotix develops radio-enhancing nanoparticles that enhance the effectiveness of radiation therapy. The company's assets include laboratories and technologies that physically enhance the fight against cancer at the cellular level. The chart below illustrates the material significance of this innovation in oncology.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Nanobiotix S.A.
Nanobiotix's balance sheet is comprised of cash in its accounts and the value of its unique nanotechnology. The market isn't evaluating these assets, but rather the potential to revolutionize cancer treatment by physically enhancing the effectiveness of radiation therapy. The chart shows how much more valuable this "hope for a breakthrough" is than its current assets.
Market to book capitalization ratio in a market segment - Oncology platforms
Nanobiotix S.A. is developing an innovative nanoparticle-based platform to enhance the effectiveness of radiation therapy in cancer treatment. Its value lies in its unique technology. This chart shows how the market valuation, based on the platform's expected success, is many times greater than its book value.
Market to book capitalization ratio for the market as a whole
Nanobiotix is a biotech company developing a new approach to cancer radiation therapy using nanoparticles. Its core value lies in its unique scientific platform and patents, not its lab equipment. This chart vividly illustrates how the market values the potential of this breakthrough technology, resulting in a market capitalization that is multiples of its book value.
Debts of the company, segment and market as a whole
NBTX - Company debts Nanobiotix S.A.
Nanobiotix, a late-stage biotech company, is using debt and equity financing to bring its radioenhancing drug to market. This chart shows how the company is raising significant capital to conduct final clinical trials and prepare for the commercial launch of its innovative oncology platform.
Market segment debts - Oncology platforms
Nanobiotix is a clinical-stage biotech company developing an innovative approach to cancer treatment using nanoparticles that enhance the effectiveness of radiation therapy. Its debt load reflects its need to fund expensive clinical trials. This chart shows how the company is raising capital to advance its promising technology toward commercialization.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Nanobiotix S.A.
Nanobiotix, a clinical-stage biopharmaceutical company, is burning through massive amounts of cash on development. Debt is the company's bridge to the future, to its first sales. This chart clearly demonstrates the extent to which this bridge is built on borrowed funds and illustrates the financial risk that directly depends on the success of its oncology platform.
Market segment debt to market segment book capitalization - Oncology platforms
Nanobiotix, a clinical-stage biotech company developing a novel approach to cancer radiation therapy using nanoparticles, compares its debt load to the overall market capitalization of the oncology sector. It shows how the company relies on raising capital to fund its breakthrough but expensive research.
Debt to book value of all companies in the market
Nanobiotix S.A. is a clinical-stage biotechnology company developing new approaches to cancer treatment. Funding for pre-market research often involves raising equity and debt capital. This market debt graph helps assess the company's funding environment for its expensive developments.
P/E of the company, segment and market as a whole
P/E - Nanobiotix S.A.
This chart for Nanobiotix S.A., a biotech company developing an innovative approach to cancer radiation therapy, illustrates investors' faith in its technology. The company may be unprofitable. This metric reflects not current profits, but rather the enormous expectations surrounding the potential success of its drug, which could change the standard of cancer treatment.
P/E of the market segment - Oncology platforms
Nanobiotix S.A. is a clinical-stage biotechnology company developing a novel, physics-based approach to cancer treatment. Its technology enhances the effects of radiation therapy directly within the tumor. This chart illustrates the average valuation in the oncology platform sector, where investors are betting on breakthrough technologies with high potential but also high risks.
P/E of the market as a whole
Nanobiotix is developing an innovative approach to cancer treatment using nanoparticles to enhance the effectiveness of radiation therapy. It is a biotech company in the research and development stage. This chart shows the overall risk appetite of investors. Comparison with it allows us to see how much Nanobiotix's valuation depends on faith in its unique technology rather than on overall market sentiment.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Nanobiotix S.A.
For Nanobiotix, a biotech company developing nanoparticles to enhance radiation therapy, this chart reflects investor expectations for future breakthroughs and the commercialization of its platform. It demonstrates the market's faith in the potential of this technology to revolutionize cancer treatment and generate significant revenue.
%20P%2FE%20Nanobiotix%20S.A.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Nanobiotix-S.A.&v=1772513791757 "Chart of the company's future (projected) P/E Nanobiotix S.A.")
Future (projected) P/E of the market segment - Oncology platforms
Nanobiotix S.A. is developing an innovative approach to cancer treatment, enhancing the effectiveness of radiation therapy. The data presented reflects expectations for profitability in the biotech sector. NBTX's position in this context may signal the degree of investor confidence in its unique NBTXR3 technology and its chances of successfully completing clinical trials.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Oncology%20platforms&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Oncology-platforms&v=1772513791770 "Future (projected) P/E graph of the market segment - Oncology platforms")
Future (projected) P/E of the market as a whole
Nanobiotix develops innovative approaches in oncology. For companies in the research stage, general market sentiment, visible on the chart, determines the availability of funding. Investors' high risk appetite allows them to attract the capital needed to conduct expensive clinical trials.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513791773 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Nanobiotix S.A.
Nanobiotix S.A. is a biotech company developing a new approach to cancer treatment using nanoparticles that enhance the effectiveness of radiation therapy. This graph depicts the trajectory of an innovative idea. It may show losses for a long time due to research costs, but a potential surge in profits will come with successful clinical trials and approval of their technology.
Profit of companies in the market segment - Oncology platforms
Nanobiotix is developing an innovative approach to cancer treatment, using nanoparticles to enhance radiation therapy. This graph of the overall profitability of oncology platforms illustrates the enormous risks and potential of biotech. Years of investment in research may not yield a return, but a single successful drug can radically transform the financial position of not only the company but the entire sector.
Overall market profit
Nanobiotix, a biopharmaceutical company working to enhance radiation therapy, is less dependent on the short-term economic cycles shown in the chart. Its success is determined by clinical trials and regulatory approvals. However, overall growth in corporate profits facilitates raising capital for long-term R&D projects vital to innovation in oncology.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Nanobiotix S.A.
Nanobiotix develops innovative approaches to cancer treatment using nanoparticles. The future profit forecast on this chart reflects market expectations regarding the completion of clinical trials and the commercialization of its platform. Investors view it as an estimate of the likelihood that the company's scientific breakthrough will translate into commercial success.
%20profit%20of%20the%20company%20Nanobiotix%20S.A.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Nanobiotix-S.A.&v=1772513791877 "Graph of future (projected) profit of the company Nanobiotix S.A.")
Future (predicted) profit of companies in the market segment - Oncology platforms
Nanobiotix is developing an innovative approach to cancer treatment using nanoparticles to enhance the effectiveness of radiation therapy. The company's future depends on the success of its clinical trials. The chart shows the projected total revenue for biotech oncology platforms, reflecting investor expectations for the entire breakthrough cancer treatment sector.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Oncology%20platforms&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Oncology-platforms&v=1772513791906 "Graph of future (predicted) profits of companies in a market segment - Oncology platforms")
Future (predicted) profit of the market as a whole
Nanobiotix S.A. is a clinical-stage biotechnology company developing oncology drugs. Its current value is determined not by revenue, but by the potential of future drugs. The overall market profit forecast affects it indirectly, through the availability of venture capital. During periods of optimism, investors are more willing to fund risky projects; during downturns, they avoid them.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513791935 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Nanobiotix S.A.
Nanobiotix is a biotech company developing a new approach to cancer treatment using nanoparticles that enhance the effectiveness of radiation therapy. The company is in the commercialization stage. This chart shows how the market values its early revenue in the context of the enormous potential of its technology, which could change the standard of cancer treatment worldwide.
P/S market segment - Oncology platforms
Nanobiotix is developing an innovative approach to cancer treatment using nanoparticles that enhance the effectiveness of radiation therapy. The chart shows the average revenue estimate for biotech companies. It helps us understand how highly investors value the potential of the company's revolutionary technology, even in the early stages of commercialization.
P/S of the market as a whole
Nanobiotix S.A. is developing an innovative approach to cancer treatment using nanoparticles to enhance radiation therapy. The company's revenue is currently minimal and depends on research progress. The chart provides an overview of how the market generally values revenue, and against this backdrop, it becomes clear to what extent expectations of future breakthroughs are factored into the current valuation.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Nanobiotix S.A.
Nanobiotix is a clinical-stage biotech company developing a novel approach to cancer treatment using nanoparticles. The valuation of such companies is based on hope. The chart is a measure of investor optimism, reflecting a high estimate of the potential future revenue that could be generated if its therapy is successful.
%20P%2FS%20Nanobiotix%20S.A.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Nanobiotix-S.A.&v=1772513791990 "The graph of the company's future (projected) P/S Nanobiotix S.A.")
Future (projected) P/S of the market segment - Oncology platforms
Nanobiotix is developing an innovative approach to cancer treatment by enhancing the effectiveness of radiation therapy using nanoparticles. This figure reflects the average future sales estimate for biotech oncology platforms. This provides an indication of how highly the market values the commercial potential of NBTXR3 technology compared to expectations for other breakthrough treatments.
%20P%2FS%20market%20segment%20graph%20-%20Oncology%20platforms&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Oncology-platforms&v=1772513792026 "Future (projected) P/S market segment graph - Oncology platforms")
Future (projected) P/S of the market as a whole
Nanobiotix S.A. is developing a revolutionary approach to cancer treatment, and its prospects are weakly linked to the overall economic cycle. This indicator reflects the market's confidence in overall revenue growth. However, for Nanobiotix, the key drivers are scientific breakthroughs and successful clinical trials, which can create enormous value regardless of the economic climate.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513792091 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Nanobiotix S.A.
Nanobiotix is a clinical-stage biotech company developing innovative cancer treatments using nanoparticles. Since its primary product has not yet been commercialized, the revenue in this chart likely comes from partnership fees and grants. The trend reflects research successes that attract funding from major players.
Sales of companies in the market segment - Oncology platforms
Nanobiotix is a biotech company developing a new approach to cancer treatment. Its key technology, NBTXR3, is based on nanoparticles that enhance the effects of radiation therapy, making it more effective in killing tumor cells. This chart shows total revenue in the oncology platform segment, allowing one to assess investment trends and the commercial potential of the entire industry.
Overall market sales
Nanobiotix S.A. is developing an innovative approach to cancer treatment using nanoparticles that enhance the effectiveness of radiation therapy. The company's success depends not on the general economic trends shown in this chart, but on breakthroughs in science and medicine. Funding and recognition in biotech are determined by research results, not by the current state of the consumer market.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Nanobiotix S.A.
Nanobiotix is a biotech company developing a new approach to cancer treatment using nanoparticles that enhance the effectiveness of radiation therapy. Its future revenue depends on the success of clinical trials and regulatory approval. This graph reflects the enormous anticipation surrounding this potential revolution in oncology.
%20sales%20of%20the%20company%20Nanobiotix%20S.A.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Nanobiotix-S.A.&v=1772513792288 "Schedule of future (projected) sales of the company Nanobiotix S.A.")
Future (projected) sales of companies in the market segment - Oncology platforms
Nanobiotix is a biotech company developing a new approach to cancer treatment using nanoparticles that enhance the effectiveness of radiation therapy. This is a risky but potentially breakthrough technology. The chart shows the overall forecast for the entire oncology platform sector. If the technology is successful, its growth could significantly outperform the average.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Oncology%20platforms&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Oncology-platforms&v=1772513792349 "Schedule of future (projected) sales of companies in the market segment - Oncology platforms")
Future (projected) sales of the market as a whole
Nanobiotix develops innovative approaches to cancer radiotherapy. The overall economic situation, reflected in this chart, has an indirect but significant impact on the company. Economic growth ensures stable funding for biotech research and allows healthcare systems to implement advanced, albeit expensive, treatments, which is important for NBTX's future.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513792364 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Nanobiotix S.A.
Nanobiotix is a biotech company developing a new approach to cancer treatment using nanoparticles. Currently, its activities primarily involve large-scale investments in research. This chart reflects the financial side of science: it shows the costs involved in creating a revolutionary product that could generate huge profits in the future.
Market segment marginality - Oncology platforms
Nanobiotix is a biotech company developing a new approach to cancer radiation therapy using nanoparticles that enhance the action of radiation. This graph shows the average profitability in the pharmaceutical industry. The potential of its technology to improve treatment standards could allow the company to achieve profitability significantly higher than the industry average in the future.
Market marginality as a whole
Nanobiotix S.A. is developing an innovative nanoparticle-based platform to enhance radiation therapy in cancer treatment. Its financial position tells a story about research expenditures, not current profits. This chart illustrates the gulf between the profitability of established corporations and biotech startups, whose value lies in future potential, not current margins.
Employees in the company, segment and market as a whole
Number of employees in the company Nanobiotix S.A.
Nanobiotix is a clinical-stage biotechnology company. Its team consists of highly qualified scientists. This graph is an important indicator of progress. Its growth indicates that the company's radiotherapy research is advancing into more complex and expensive clinical trials, moving closer to commercialization.
Share of the company's employees Nanobiotix S.A. within the market segment - Oncology platforms
Nanobiotix is developing a revolutionary approach to cancer treatment, enhancing the effectiveness of radiation therapy with nanoparticles. This is at the cutting edge of science, requiring unique specialists. This indicator reflects the share of scientists the company attracts in the rare field of nanomedicine and demonstrates its role as a center of excellence, home to the industry's intellectual capital.
Number of employees in the market segment - Oncology platforms
Nanobiotix S.A. is a clinical-stage biotechnology company developing a new approach to cancer treatment using nanoparticles that enhance the effectiveness of radiation therapy. This graph shows how staffing changes as research progresses. Hiring is often accelerated before key phases of clinical trials or in preparation for market launch.
Number of employees in the market as a whole
Nanobiotix S.A. develops innovative approaches in oncology. The company's activities are funded by venture capital and partnerships, not the current economic situation, as illustrated by this chart. Its valuation depends on scientific breakthroughs and successful clinical trials that could change the paradigm of cancer treatment.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Nanobiotix S.A. (NBTX)
Nanobiotix S.A. is a clinical-stage biotech company. Its market capitalization is based on the potential of its scientific platform, not current revenue. This chart demonstrates investors' faith in the technology. Enormous potential value accrues from a small team of scientists, resulting in a very high ratio per employee.
%20of%20the%20company%20Nanobiotix%20S.A.%20(NBTX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Nanobiotix-S.A.-NBTX&v=1772513792727 "Chart of market capitalization per employee (in thousands of dollars) of the company Nanobiotix S.A. (NBTX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Oncology platforms
Nanobiotix is a biotech company developing a new approach to cancer treatment using nanoparticles. Its market capitalization is based on the potential of a breakthrough technology being developed by a relatively small team of scientists. This chart shows the company's high market valuation of intellectual capital per scientist.
%20by%20market%20segment%20-%20Oncology%20platforms&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Oncology-platforms&v=1772513792765 "Market capitalization per employee (in thousands of dollars) by market segment - Oncology platforms")
Market capitalization per employee (in thousands of dollars) for the overall market
Nanobiotix develops innovative approaches to cancer treatment using nanoparticles to enhance radiation therapy. This chart shows the valuation of biotech innovations. The high market capitalization per employee reflects the enormous potential of their unique technology, which could change the standard of oncology treatment.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513792810 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Nanobiotix S.A. (NBTX)
Nanobiotix is a clinical-stage biotech company developing a platform to enhance radiation therapy for cancer treatment. Like many biotech companies, their profitability is a matter of the future. This graph likely shows a negative value, reflecting high R&D costs per employee. It measures the capital burn per scientist in pursuit of scientific breakthroughs.
%20Chart%20Nanobiotix%20S.A.%20(NBTX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Nanobiotix-S.A.-NBTX&v=1772513792862 "Company Profit Per Employee (in thousands of dollars) Chart Nanobiotix S.A. (NBTX)")
Profit per employee (in thousands of dollars) in the market segment - Oncology platforms
Nanobiotix (NBTX) is an R&D biotech company (nanoparticles for "enhancing" radiation therapy). This chart shows the benchmark for "Oncology" (R&D). The average profit per employee in this sector (venture R&D) is *negative*. This benchmark reflects the "burning" of cash in the hopes of one or two mega-successes. The entire sector is an R&D race.
%20in%20the%20market%20segment%20-%20Oncology%20platforms&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Oncology-platforms&v=1772513792898 "Chart of profit per employee (in thousands of dollars) in the market segment - Oncology platforms")
Profit per employee (in thousands of dollars) for the market as a whole
Nanobiotix S.A. is a clinical-stage biotech developing a platform to enhance radiation therapy for cancer treatment. The company does not yet have stable profits, as it is focused on R&D and clinical trials. This graph will likely show negative or zero profit per employee, which is typical for R&D biotech companies before drug approval.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513792938 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Nanobiotix S.A. (NBTX)
Nanobiotix develops innovative cancer treatments. This chart shows the financial return on its research and development. The revenue per employee trend reflects key commercialization milestones, such as partnerships or approvals, when a small team of scientists can generate significant value.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Nanobiotix-S.A.-NBTX&v=1772513792956 "Sales chart per company employee Nanobiotix S.A. (NBTX)")
Sales per employee in the market segment - Oncology platforms
Nanobiotix (NBTX) is a clinical-stage biotech company developing a new approach to cancer radiation therapy. At this stage, the company has virtually no product revenue, but it does have a staff of scientists. This graph will show extremely low or zero productivity. This indicator will only begin to increase if their drug is approved and commercial sales begin.
Sales per employee for the market as a whole
Nanobiotix S.A. is a biotech company developing a platform to enhance radiation therapy. During the R&D phase, this metric is typically low, as the large research staff generates little revenue. This graph is an indicator of the future: if commercial success occurs, sales will skyrocket, and the staff's efficiency metric will soar, reflecting the value of their intellectual property.
Short shares by company, segment and market as a whole
Shares shorted by company Nanobiotix S.A. (NBTX)
Nanobiotix (NBTX) is a biotech company at the intersection of physics and medicine. Their key development, NBTXR3, is designed to enhance radiation therapy by making cancer cells more vulnerable. This figure reflects market uncertainty. Are investors betting that clinical trials won't prove a significant benefit, or that the commercialization process will prove too difficult?
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Nanobiotix-S.A.-NBTX&v=1772513793090 "Short Shares Chart for the Company Nanobiotix S.A. (NBTX)")
Shares shorted by market segment - Oncology platforms
Nanobiotix (NBTX) is a French biotech company that has developed a radiation therapy "booster" (NBTXR3), which is injected into tumors to enhance the effectiveness of radiation. This chart shows the odds against the entire biotech sector. The rising odds against the industry reflect investor skepticism about the commercialization of this new technology.
Shares shorted by the overall market
Nanobiotix (NBTX) is a biotech company developing an innovative approach to cancer radiation therapy using nanoparticles. It is a science-intensive R&D company. This chart measures overall market pessimism. When investors are fearful (the indicator rises), they sell off speculative biotechs without profits, fearing that the companies will need cash in poor market conditions.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Nanobiotix S.A. (NBTX)
Nanobiotix is a French biotech company developing a technology to "enhance" radiation therapy using nanoparticles. It's a breakthrough, but speculative idea. This chart measures the level of hope. It shows when the stock is "overbought" on the euphoria of trial data or "oversold" amid doubts and delays.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Nanobiotix-S.A.-NBTX&v=1772513793246 "RSI 14 indicator chart for the company's stock Nanobiotix S.A. (NBTX)")
RSI 14 Market Segment - Oncology platforms
Nanobiotix is a biotech company developing an innovative approach to radiation therapy. Their nanoparticles (NBTXR3) are designed to enhance the delivery of radiation within tumors. This graph measures the collective excitement in the oncology biotech sector. It helps determine whether the entire segment is overheated by expectations of clinical success.
RSI 14 for the overall market
Nanobiotix (NBTX) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast NBTX (Nanobiotix S.A.)
Nanobiotix is a biotech company changing the approach to radiation therapy. Its NBTXR3 platform is designed to enhance the effects of radiation within tumors. This chart shows the analyst consensus forecast. Their targets are based on clinical data, regulatory approval prospects, and partnerships.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-NBTX-Nanobiotix-S.A.&v=1772513793420 "A chart showing analyst consensus forecasts for the expected stock price. NBTX (Nanobiotix S.A.)")
The difference between the consensus estimate and the actual stock price NBTX (Nanobiotix S.A.)
Nanobiotix is a French biotech company with a speculative technology. They have developed NBTXR3 nanoparticles, which are supposed to enhance the effects of radiation therapy by activating within tumors. It's a risky bet. This chart shows how much analysts believe in their R&D platform and the chances of approval for this breakthrough treatment. It shows the gap between the target price and the current price.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-NBTX-Nanobiotix-S.A.&v=1772513793439 "A chart showing the difference between the consensus forecast and the actual stock price. NBTX (Nanobiotix S.A.)")
Analyst consensus forecast for stock prices by market segment - Oncology platforms
Nanobiotix is a biotech company developing "radioenhancers"—nanoparticles to enhance cancer radiation therapy. This is a bet on a new R&D platform. This chart shows analysts' overall expectations for the entire oncology platform sector. It reflects whether experts believe in the commercial success of these new treatment approaches.
Analysts' consensus forecast for the overall market share price
Nanobiotix is a biotech company developing a new class of drugs (nanoparticles) to enhance cancer radiation therapy. This is a high-risk, high-expectation sector. This chart shows the overall risk appetite. When analysts are optimistic, investors are more willing to fund the long-term research and development that Nanobiotix's future depends on.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Nanobiotix S.A.
Nanobiotix is a biotech company at the forefront of physics and oncology. Their unique platform (NBTXR3) is a radio-enhancer: nanoparticles that are injected into tumors to focus and enhance the effects of radiation therapy. This chart is a pure assessment of their R&D potential. It reflects the market's confidence in their breakthrough science, clinical trial results, and their chances of regulatory approval.
AKIMA Market Segment Index - Oncology platforms
Nanobiotix is a pioneer in cancer physics, developing nanoparticles designed to enhance the lethality of radiation therapy within tumors. The chart shows the average score for this entire segment. This average provides a baseline. Does Nanobiotix's new approach allow it to demonstrate superior potential compared to the typical biotech company, or are its risks holding it back from the industry benchmark?
The AKIM Index for the overall market
Nanobiotix is a nanomedicine pioneer using physics to improve the effectiveness of cancer radiation therapy. This chart, showing the market average, is a "risk appetite" indicator. It helps us understand whether this scientific story is driven by its own clinical news or by general investor optimism in biotech.
